Purpose
=======

Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disease, more common in children. We present baseline data on the juvenile LS (jLS) cohort from the CARRAnet observational registry of pediatric rheumatologic disorders.

Methods
=======

We performed a cross-sectional baseline analysis of registry data for jLS.

Results
=======

Data were available on 44 children. 81.8% were female and 88.6% were Caucasian, of which 13.6% were Latino. Mean age at onset was 8.2 years (± 4.0), yet first evaluation by a pediatric rheumatologist was 9.9 years (± 4.2). Reported subtypes were: 34 linear scleroderma (LiScl: 25 trunk/limbs, 9 face/neck), 7 with circumscribed morphea (CM: 5 deep, 2 superficial), 6 with generalized morphea (GenM), 3 with eosinophilic fasciitis (EF), and 1 with pansclerotic morphea. There were 5 cases of mixed morphea (2 CM and LiScl, 1 with facial LiScl and GM, 2 with EF and linear lesions). Eight subjects had new lesions at time of enrollment. Features of active lesions included extension of existing lesions (13), warmth (13), erythematous/violacious color (13), and skin induration at lesion perimeter (10). Damage included subcutaneous atrophy (36), hyperpigmentation (35), dermal atrophy (31), hypopigmentation (19), hair loss (17), muscle atrophy (13), joint contracture (10), limb shortening (5), and hemifacial atrophy(1). Only three patients had extracutaneous manifestations, including two with arthritis. ANA positivity was found in 45% of tested patients, otherwise there were no consistent laboratory or imaging abnormalities. Table [1](#T1){ref-type="table"}.

             Antinuclear antibody   Elevated IgG   Eosinophilia   Abnormal aldolase   Abnormal creatine kinase   Abnormal CNS imaging   Abnormal GI study
  ---------- ---------------------- -------------- -------------- ------------------- -------------------------- ---------------------- -------------------
  Positive   14                     6              5              3                   1                          1                      3
  Negative   17                     20             30             16                  24                         10                     3
  Unknown    13                     16             7              23                  17                         32                     36
  Total      44                     42             42             42                  42                         43                     42

Mean physician global assessment was 1.61 (range 0-8) and mean CHAQ score was 0.19 (0-1.13). On a visual analog scale (0-10), mean parent/subject score of overall well-being was 1.80 (± 1.66) and pain was 1.41 (±2.03). Health related quality of life was reported as excellent in 13, very good in 22, good in 7, and poor in 2 subjects. A worst ever and current ACR functional class \> I was reported in 33% and 20.5%, respectively. Medications used are listed in table [2](#T2){ref-type="table"}.

                 Oral methotrexate   Subcutaneous methotrexate   Mycophenolate mofetil   Intravenous corticosteroids   Longterm daily corticosteroids
  -------------- ------------------- --------------------------- ----------------------- ----------------------------- --------------------------------
  Subjects (%)   21/42 (50%)         15/42 (36%)                 15/42 (36%)             28-36 (78%)                   17/35 (49%)
  Current use    12                  4                           4                       5                             5
  Past use       9                   11                          11                      23                            12

Conclusion
==========

jLS is reported more frequently in females and Caucasians in the CARRA Registry. LiScl is the most common lesion subtype, representing 77% of all patients. 45% of the jLS cohort is ANA positive. Subcutaneous and oral MTX, MMF, and pulse CS are the most common medications used for treatment. There is an almost 2 year delay in referral to pediatric rheumatology. There is significant morbidity associated with jLS with 30% reporting limitation in functional capacity.
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